A Dose of Reality for Rational Therapies  

Oleh:

[s.n]

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Nature Biotechnology: The Science and Business of Biotechnology vol. 23 no. 3 (Mar. 2005), page 267-268.
Topik: reality; reality; rational therapies

Ketersediaan

Perpustakaan Pusat (Semanggi) Nomor Panggil: NN9.2 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Many of biotech's greatest therapeutic successes are drugs used as adjuncts to conventional cancer therapies. Erythropoietin a and granulocyte macrophage colony stimulating factor are blockbusters that ameliorate the harmful effects of cytotoxic chemotherapy regimes. Interferon a was for many years the therapy of choice for use with traditional chemotherapy in certain leukemias and multiple myeloma. Now molecularly targeted biotech drugs monoclonal antiodies and small molecules that inhibit protein kinases activated by mutations and chromosomal rearrangements occuring in tumors, have investors and analysts purring about their potential as cancer therapies. The approvals of monoclonal antibodies herceptin (trastuzumab) and erbitux (cetuximab) and of the small molecule tarceva (erlotinib) all of which target mutated receptor tyrosine kinases are further fueling the enthusiasm. Several taks at last month's miami nature biotechnology winter symposium highlighted the expanding number of kinases, phosphatidylinositol 3-kinase, Akt, PTEN, mTOR, the Ras/Raf/MEK pathway and cell cycle proteins CDKs/cyclins being targeted by drug developers. With over 30 kinase inhibitors currently in clinical development and around 518 protein kinases identified in the human genome, there appears to be plenty of low hanging fruit for companies to pick.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali